PapersPMID:39903510
The mystery of methylene blue and its role in managing post-cardiac surgery vasoplegic shock.
- findings
- 2
- compound
- 1
- endpoints
- 2
- no difference found
- 1
- Study, every finding
- cohort
- Dose studied, every finding
- 2 mg/kg intravenous bolus followed by 0.5 mg/kg/h infusion for 12 h
What moved
How to read these marks →“The patients in the MB group (n = 84) have a lower intensive care unit stay duration in days (9 ± 8 days) vs. (16 ± 6.9) in the control group (n = 116).”
- Population
- Adults with norepinephrine-refractory vasoplegic syndrome after cardiac surgery with cardiopulmonary bypass; 84 given methylene blue within 24 h postoperatively versus 116 not given it, all on norepinephrine; retrospective single-centre cohort, MB group significantly younger
What did not
- No detected effect on all-cause mortality
very limited
“The study’s primary endpoint, In-hospital mortality, was insignificant between the two groups (38% in the MB group vs. 43% in the control group).”
- Population
- Adults with norepinephrine-refractory vasoplegic syndrome after cardiac surgery with cardiopulmonary bypass; 84 given methylene blue within 24 h postoperatively versus 116 not given it, all on norepinephrine; retrospective single-centre cohort; in-hospital horizon
Study record
- Design
- cohort study
- Species
- human
- Population
- Patients with norepinephrine-refractory vasoplegic syndrome after cardiac surgery with cardiopulmonary bypass (single-center retrospective); 84 received methylene blue within 24 h postoperatively, 116 did not
- Participants
- 200
- Comparator
- no treatment
- Duration
- not reported
- Endpoints measured
- 8